Mechanism-based cancer therapy: resistance to therapy, therapy for resistance
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanism-based cancer therapy: resistance to therapy, therapy for resistance
Authors
Keywords
-
Journal
ONCOGENE
Volume 34, Issue 28, Pages 3617-3626
Publisher
Springer Nature
Online
2014-09-29
DOI
10.1038/onc.2014.314
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
- (2015) James Andrew McCubrey et al. Oncotarget
- Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
- (2014) E Alba et al. BRITISH JOURNAL OF CANCER
- Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS-ERK Signaling
- (2014) M. Will et al. Cancer Discovery
- Transposon activation mutagenesis as a screening tool for identifying resistance to cancer therapeutics
- (2013) Li Chen et al. BMC CANCER
- Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
- (2013) Howard A. Burris CANCER CHEMOTHERAPY AND PHARMACOLOGY
- High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development
- (2013) D. Lin et al. CANCER RESEARCH
- Targeting the Tumor Microenvironment: From Understanding Pathways to Effective Clinical Trials
- (2013) H. Fang et al. CANCER RESEARCH
- Targeting PI3K, HER2 and the IL-8/JAK2 axis in metastatic breast cancer: Which combination makes the whole greater than the sum of its parts?
- (2013) Adrian Britschgi et al. DRUG RESISTANCE UPDATES
- Everolimus in Combination with Exemestane: A Review of its Use in the Treatment of Patients with Postmenopausal Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- (2013) Sohita Dhillon DRUGS
- Molecular-targeted agents combination therapy for cancer: Developments and potentials
- (2013) Feifei Li et al. INTERNATIONAL JOURNAL OF CANCER
- Next-Generation Sequencing Reveals High Concordance of Recurrent Somatic Alterations Between Primary Tumor and Metastases From Patients With Non–Small-Cell Lung Cancer
- (2013) Stéphane Vignot et al. JOURNAL OF CLINICAL ONCOLOGY
- Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib
- (2013) Alfonso Quintás-Cardama et al. LEUKEMIA RESEARCH
- Selection and adaptation during metastatic cancer progression
- (2013) Christoph A. Klein NATURE
- Tumour heterogeneity in the clinic
- (2013) Philippe L. Bedard et al. NATURE
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
- (2013) Meghna Das Thakur et al. NATURE
- Influence of tumour micro-environment heterogeneity on therapeutic response
- (2013) Melissa R. Junttila et al. NATURE
- Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
- (2013) Muhammed Murtaza et al. NATURE
- Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis
- (2013) Eric P Rahrmann et al. NATURE GENETICS
- Development of PI3K inhibitors: lessons learned from early clinical trials
- (2013) Jordi Rodon et al. Nature Reviews Clinical Oncology
- High-Throughput 3D Screening Reveals Differences in Drug Sensitivities between Culture Models of JIMT1 Breast Cancer Cells
- (2013) Vesa Hongisto et al. PLoS One
- Cancer Genome Landscapes
- (2013) B. Vogelstein et al. SCIENCE
- Tumor heterogeneity in the clinic: is it a real problem?
- (2013) Filip Janku Therapeutic Advances in Medical Oncology
- Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
- (2012) Dorte L. Nielsen et al. BREAST
- Increased signalling of EGFR and IGF1R and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
- (2012) A Gallardo et al. BRITISH JOURNAL OF CANCER
- JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer
- (2012) Adrian Britschgi et al. CANCER CELL
- Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
- (2012) Taru Muranen et al. CANCER CELL
- PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
- (2012) F. Janku et al. CANCER RESEARCH
- Intratumor Heterogeneity: Evolution through Space and Time
- (2012) C. Swanton CANCER RESEARCH
- Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer
- (2012) S. Chandarlapaty et al. CLINICAL CANCER RESEARCH
- Discrepancies between primary tumor and metastasis: A literature review on clinically established biomarkers
- (2012) Stéphane Vignot et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis
- (2012) Robert L Yauch et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches
- (2012) Antonella De Luca et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia
- (2012) Maria Karvela et al. Expert Review of Anticancer Therapy
- The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer
- (2012) Julia A Beaver et al. Future Oncology
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer
- (2012) Stephan P Tenbaum et al. NATURE MEDICINE
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rescue Screens with Secreted Proteins Reveal Compensatory Potential of Receptor Tyrosine Kinases in Driving Cancer Growth
- (2012) Fred Harbinski et al. Cancer Discovery
- PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
- (2011) Leiping Wang et al. BMC CANCER
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
- (2011) K. P. Hoeflich et al. CANCER RESEARCH
- A Blueprint for Advancing Genetics-Based Cancer Therapy
- (2011) William R. Sellers CELL
- The Evolving War on Cancer
- (2011) Daniel A. Haber et al. CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- EGFR-targeted therapy
- (2011) Loredana Vecchione et al. EXPERIMENTAL CELL RESEARCH
- Whole genome sequencing of matched primary and metastatic acral melanomas
- (2011) S. Turajlic et al. GENOME RESEARCH
- Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways
- (2011) James A. McCubrey et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib
- (2011) Carlo Gambacorti-Passerini et al. JNCI-Journal of the National Cancer Institute
- A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer
- (2011) M. Hidalgo et al. MOLECULAR CANCER THERAPEUTICS
- A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer
- (2011) Markus K Muellner et al. Nature Chemical Biology
- Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway–dependent and PI3K pathway–independent mechanisms
- (2011) Pixu Liu et al. NATURE MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
- (2011) V Serra et al. ONCOGENE
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- PTEN, PIK3CA, p-AKT, and p-p70S6K Status
- (2010) Francisco J. Esteva et al. AMERICAN JOURNAL OF PATHOLOGY
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
- (2010) Teemu T. Junttila et al. BREAST CANCER RESEARCH AND TREATMENT
- Incorporation of multicellular spheroids into 3-D polymeric scaffolds provides an improved tumor model for screening anticancer drugs
- (2010) Won Jin Ho et al. CANCER SCIENCE
- Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab
- (2010) Fabrice Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
- (2010) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
- (2010) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic variegation of clonal architecture and propagating cells in leukaemia
- (2010) Kristina Anderson et al. NATURE
- The patterns and dynamics of genomic instability in metastatic pancreatic cancer
- (2010) Peter J. Campbell et al. NATURE
- Distant metastasis occurs late during the genetic evolution of pancreatic cancer
- (2010) Shinichi Yachida et al. NATURE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
- (2010) D Ercan et al. ONCOGENE
- PiggyBac Transposon Mutagenesis: A Tool for Cancer Gene Discovery in Mice
- (2010) R. Rad et al. SCIENCE
- BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation
- (2010) R. B. Corcoran et al. Science Signaling
- PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
- (2009) S. Wee et al. CANCER RESEARCH
- In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
- (2009) K. P. Hoeflich et al. CLINICAL CANCER RESEARCH
- Inferring tumor progression from genomic heterogeneity
- (2009) N. Navin et al. GENOME RESEARCH
- Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
- (2009) A Hochhaus et al. LEUKEMIA
- Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
- (2009) Pasi A. Jänne et al. NATURE REVIEWS DRUG DISCOVERY
- MEK1 mutations confer resistance to MEK and B-RAF inhibition
- (2009) C. M. Emery et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- 1 Integrin Inhibition Dramatically Enhances Radiotherapy Efficacy in Human Breast Cancer Xenografts
- (2008) C. C. Park et al. CANCER RESEARCH
- Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
- (2008) P. J.A. Eichhorn et al. CANCER RESEARCH
- Integrin Agonists as Adjuvants in Chemotherapy for Melanoma
- (2008) M. A. Schwartz et al. CLINICAL CANCER RESEARCH
- Cotargeting survival signaling pathways in cancer
- (2008) Steven Grant JOURNAL OF CLINICAL INVESTIGATION
- Mitochondrial regulation by c-Myc and hypoxia-inducible factor-1 controls sensitivity to econazole
- (2008) Y. Yu et al. MOLECULAR CANCER THERAPEUTICS
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
- Tamoxifen: Catalyst for the change to targeted therapy
- (2007) V. Craig Jordan EUROPEAN JOURNAL OF CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started